Together, these studies confirmed published observations that the CEA-TCB immunotherapy markedly enhances anti-tumor responses by CD8 T cells, and these are further amplified by combination therapy with aPD-L1 (79). The gene discussed is CEACAM5; the disease is neoplasm.